Literature DB >> 15099949

Cystectomy for immature teratoma of the ovary.

Mario E Beiner1, Walter H Gotlieb, Yaacov Korach, Alon Shrim, David Stockheim, Yaacov Segal, Eduard Fridman, Gilad Ben-Baruch.   

Abstract

OBJECTIVES: Most patients with malignant ovarian germ cell tumors (MOGCT) of the ovary are in their reproductive years and wish to preserve fertility. Because of the excellent response to chemotherapy, the standard of care is unilateral salpingo-oophorectomy (USO), but some patients undergo cystectomy only before final pathology. In view of the lack of information concerning the outcome following cystectomy in germ cell tumors, we retrospectively evaluated the clinical outcome of patients who underwent cystectomy only as part of their surgical treatment.
METHODS: The clinical and pathological records of 38 patients diagnosed with MOGCT, treated and followed in the department of gynecologic oncology were reviewed. Eight patients underwent cystectomy only at their initial surgery and are the subjects of this study.
RESULTS: All the eight patients who underwent cystectomy were diagnosed with immature teratoma (three grade 1, four grade 2, and one grade 3) on final pathology following surgery. All except three patients (two with grade 1 and one with grade 2 disease) received adjuvant chemotherapy. Follow-up was available for all the patients, with a median duration of 4.7 years. No recurrences were observed during this period. Three patients delivered a total of seven babies.
CONCLUSIONS: Cystectomy followed by adjuvant chemotherapy appeared satisfactory for apparent early-stage immature teratoma when close follow-up was carried out. It is still unclear whether cystectomy alone will also be safe. Further studies will need to address this issue.

Entities:  

Mesh:

Year:  2004        PMID: 15099949     DOI: 10.1016/j.ygyno.2004.01.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

Review 2.  Update on the management of ovarian torsion in children and adolescents.

Authors:  Abdul Ghani Nur Azurah; Zakaria Wan Zainol; Ani Amelia Zainuddin; Pei Shan Lim; Aqmar Suraya Sulaiman; Beng Kwang Ng
Journal:  World J Pediatr       Date:  2014-12-29       Impact factor: 2.764

3.  Management of bilateral malignant ovarian germ cell tumors: Experience of a single institute.

Authors:  Ting Zhao; Yan Liu; Hongyuan Jiang; Hao Zhang; Yuan Lu
Journal:  Mol Clin Oncol       Date:  2016-05-30

4.  [Immature teratoma of the ovary: about a case].

Authors:  Wail Bouzoubaa; Sofia Jayi; Fatima Zohra Fdili Alaoui; Hikmat Chaara; Moulay Abdelilah Melhouf
Journal:  Pan Afr Med J       Date:  2017-08-09

5.  Fertility sparing approach as the standard of care in young patients with immature teratomas.

Authors:  Christos Iavazzo; George Vorgias; Paraskevi Evangelia Iavazzo; Ioannis D Gkegkes
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-03-15

6.  Early stage ovarian immature teratoma, surveillance or chemotherapy after surgery? A propensity score matched analysis.

Authors:  Xinyue Zhang; Jie Yang; Jinhui Wang; Ying Zhang; Jiaxin Yang
Journal:  Gynecol Oncol Rep       Date:  2022-04-04

7.  Successful infertility treatment following fertility-sparing surgery and chemotherapy for ovarian immature teratoma: a case report and a literature review.

Authors:  Hiroshi Matsushita; Hirohiko Tani
Journal:  Reprod Med Biol       Date:  2011-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.